Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 85,906 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Anxiety
Interventions: Educational video; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: capecitabine, ixabepilone; Drug
Lead sponsor: R-Pharm; Industry
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Invasive Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Interventions: Propranolol; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Trichotillomania
Interventions: Habit Reversal Training; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 7 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Coronary Artery Disease
Interventions: Simvastatin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Laparoscopic Surgery
Interventions: Fentanyl, Labetalol, Esmolol; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy
Interventions: PF-04308515, Prednisone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Acute Coronary Syndrome
Interventions: Intervention arm: Text Message Intervention; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Childhood Obesity
Interventions: Dairy Products, Dairy Servings; Dietary Supplement
Lead sponsor: University of Kansas; Other
Eligibility: 10 Years to 13 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Lawrence, Kansas

Conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: Bendamustine hydrochloride, Bortezomib, Dexamethasone; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Gamma Tocopherol Serum Levels
Interventions: Gamma tocopherol; Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Retinitis Pigmentosa
Interventions: BS01; Drug
Lead sponsor: Bionic Sight LLC; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Teaneck, New Jersey

Conditions: Cognitive Function
Interventions: Placebo Control Form 1, Clarity Active Study Product 1.1 Usage, Placebo Control Form 2, Clarity Active Study Product 2.1 Usage, Placebo Control Form 3, Clarity Active Study Product 3.1 Usage, Clarity Active Study Product 3.2 Usage, Placebo Control Form 4, Clarity Active Study Product 4.1 Usage, Placebo Control Form 5, Clarity Active Study Product 5.1 Usage, Clarity Active Study Product 5.2 Usage, Placebo Control Form 6, Clarity Active Study Product 6.1 Usage, Placebo Control 6.1.0, Clarity Active Study Product 6.1.1 Usage, Clarity Active Study Product 6.1.2 Usage; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 4,794 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Prostate Cancer Metastatic
Interventions: DOCETAXEL (XRP6976), CABAZITAXEL (XRP6258), Prednisone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 14
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Indianapolis, Indiana + 10 more

Conditions: Rheumatoid Arthritis
Interventions: Veltuzumab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: La Mesa, California • Los Angeles, California • Upland, California + 5 more

Conditions: Myelodysplastic Syndromes
Interventions: Azacitidine Level 1, Azacitidine Level 0, Iadademstat Level 1, Iadademstat Level 0; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Metastatic Breast Cancer
Interventions: 17B-estradiol, Letrozole, Anastrozole, Exemestane; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 3
States / cities: Springfield, Massachusetts • Rochester, Minnesota • Lebanon, New Hampshire

Conditions: Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel
Interventions: Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics; Drug · Device
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Pneumococcal Infections
Interventions: V114 Lot 1, V114 Lot 2, Prevnar 13™; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 1,051 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 30
States / cities: Birmingham, Alabama • Dothan, Alabama • Jonesboro, Arkansas + 27 more

Conditions: Small Cell Lung Cancer
Interventions: ZL-1310, Tarlatamab, Durvalumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 7
States / cities: Goodyear, Arizona • Tampa, Florida • Zion, Illinois + 4 more

Conditions: HIV Infections, Hepatic Steatosis, Insulin Resistance
Interventions: Pioglitazone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteoarthritis, Traumatic Arthritis, Avascular Necrosis of the Femoral Condyle, Moderate Varus, Valgus, Flexion Deformities
Interventions: NexGen LPS-Flex Mobile Bearing Knee; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: Not listed
Enrollment: 266 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2021
U.S. locations: 3
States / cities: Tamarac, Florida • Auburn Hills, Michigan • Knoxville, Tennessee

Conditions: Macular Telangiectasia Type 2 (MacTel)
Interventions: NT-501/revakinagene taroretcel-lwey; Combination Product
Lead sponsor: Neurotech Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 23
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 19 more

Conditions: Systemic Lupus Erythematosus
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more

Search by objective public record fields.

Patient Satisfaction Study: Clean Intermittent Self-Catheterization Teaching

BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer

Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients

Habit Reversal Training for Children and Adolescents With Trichotillomania

Effect of Acute Statin Treatment in Patients Undergoing Percutaneous Coronary Intervention

Labetalol and Esmolol: Vital Signs and Post Operative Pain Management

Single Dose Study Of PF-04308515 And Prednisone On Carbohydrate

Piloting Text Messages to Promote Positive Affect and Physical Activity

Substrate Oxidation in Children in Response to High and Low Dairy Intake

Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Evaluation of a Short Course of Gamma Tocopherol Supplementation in Adult Subjects

BS01 in Patients With Retinitis Pigmentosa

Radicle Clarity 24: A Study of Health and Wellness Products on Cognitive Function and Related Health Outcomes

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis

Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome

ER Reactivation Therapy for Breast Cancer

Pharmacokinetics of Neostigmine and Glycopyrrolate

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

Pioglitazone to Treat Fatty Liver in People With HIV Infection

Prospective Multicenter Post Approval Study of the LPS-Flex Mobile Bearing Knee

Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)